ARTICLE | Clinical News

C225 epidermal growth factor receptor: Began two Phase Ib/IIa trials, one testing the agent alone, and the other combining it with cisplatin. Each 24-patient tr

May 30, 1995 7:00 AM UTC

ImClone Systems Inc. (IMCL), New York Product: C225 epidermal growth factor receptor (EGFr) antagonist Indication: EGFr-positive cancers of the head, neck and lung Status: Began two Phase Ib/IIa tria...